AMRX - Amneal Pharmaceuticals, Inc.

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue1,662,9911,033,6541,018,225866,280
Cost of Revenue926,180503,994446,498367,054
Gross Profit736,811529,660571,727499,226
Operating Expenses
Research Development194,190171,420179,019136,870
Selling General and Administrative230,435109,046118,757109,679
Non Recurring----
Others----
Total Operating Expenses1,350,805784,460744,274639,050
Operating Income or Loss312,186249,194273,951227,230
Income from Continuing Operations
Total Other Income/Expenses Net-514,908-77,871-59,130-51,648
Earnings Before Interest and Taxes312,186249,194273,951227,230
Interest Expense-143,571-71,061-55,283-45,835
Income Before Tax-202,722171,323214,821175,582
Income Tax Expense-1,4191,9985,3954,951
Minority Interest391,61310,1579,3458,270
Net Income From Continuing Ops-201,303169,325209,426170,631
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-169,726167,648207,378169,451
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-20,920167,648207,378169,451